

## FORM 7

### MONTHLY PROGRESS REPORT

Name of Listed Issuer: AION THERAPEUTIC INC. (the "Issuer")

Trading Symbol: AION

Number of Outstanding Listed Securities: 124,804,794

Date: May 31, 2021

#### **Report on Business**

- 1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.**

The Issuer is focused on utilizing science, research, treatment, data mining and artificial intelligence to develop combinatorial pharmaceuticals, nutraceuticals and cosmeceuticals using compounds from cannabis (cannabinoids), psychedelic mushrooms (psilocybin), fungi, and other psychedelic formulations and their related medicinal global intellectual property protection.

On May 18, 2021, the Issuer and Apollon Formularies plc ("Apollon") announced that their joint testing has revealed their combined formulations to be effective in killing HER2+ breast cancer cells grown in 3D cell culture via three separate mechanisms: direct cell cytotoxicity, immune stimulated T-cell cytotoxicity, and macrophage induced phagocytosis. HER2- positive constitutes approximately 20% of all breast cancers.

The testing was performed by BIOENSIS, an independent, pre-clinical predictive pharmaceutical testing laboratory. The medical cannabis formulations were developed by Apollon's affiliate, Apollon Formularies Jamaica Limited ("Apollon Jamaica") and the medicinal mushroom formulations were developed by AI Pharmaceuticals Jamaica Limited ("AI Pharma"), a wholly-owned subsidiary of the Issuer.

The testing results showed that Apollon Jamaica's medical cannabis formulations were particularly effective in killing living HER2+ cancer cells directly (direct cytotoxicity), while AI Pharma's medicinal mushroom formulations were most effective in stimulating the immune system's T-cell production to attack and kill HER2+ cancer cells and through macrophage induced phagocytosis. When the two formulations were combined, nearly 100% of HER2+ breast cancer cells in 3D cell cultures were killed through the three different pathways.

**2. Provide a general overview and discussion of the activities of management.**

During the month of May 2021, management has been focused on furthering its development of combinatorial pharmaceuticals, nutraceuticals and cosmeceuticals using compounds from cannabis (cannabinoids), psychedelic mushrooms (psilocybin), fungi, and other psychedelic formulations and their related medicinal global intellectual property protection.

**3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.**

None.

**4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.**

None.

**5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.**

None.

**6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.**

None.

**7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.**

None.

- 8. Describe the acquisition of new customers or loss of customers.**  
None.
- 9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.**  
None.
- 10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.**  
None.
- 11. Report on any labour disputes and resolutions of those disputes if applicable.**  
None.
- 12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.**  
None.
- 13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.**  
None.
- 14. Provide details of any securities issued and options or warrants granted.**  
None.

**15. Provide details of any loans to or by Related Persons.**

None.

**16. Provide details of any changes in directors, officers or committee members.**

None.

**17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.**

In March 2020, the World Health Organization declared a global pandemic related to the outbreak of the novel strain of coronavirus, specifically identified as "COVID-19". This has resulted in governments worldwide enacting emergency measures to combat the spread of the virus. These measures which include the implementation of travel bans, self-imposed quarantine periods and social distancing have caused material disruption to businesses resulting in a global economic disruption. Global equity markets have experienced historic volatility and weakness. Governments and central banks have reacted with significant monetary and fiscal interventions designed to stabilize domestic economic conditions. The duration and impact of the COVID-19 outbreak is unknown at this time, as is the efficacy of the government and central bank interventions.

The Issuer had operated primarily on a virtual basis prior to the COVID-19 pandemic. Therefore, the implementation of travel bans, self-imposed quarantine periods, social distancing and general closure of non-essential businesses in response to COVID-19 has not materially impacted the Issuer with its day-to-day operations. Furthermore, the Issuer does not expect the COVID-19 pandemic to have a material adverse effect on the Issuer's results of operations.

## Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated June 2, 2021.

Graham Simmonds  
Name of Director or Senior  
Officer

"Graham Simmonds" (signed)  
Signature

Chief Executive Officer  
Official Capacity

<b><i>Issuer Details</i></b> Name of Issuer AION THERAPEUTIC INC.	For Month End May 2021	Date of Report YY/MM/DD 21/06/02
Issuer Address 45 Sheppard Avenue East, Suite 703		
City/Province/Postal Code Toronto, Ontario, M2N 5W9	Issuer Fax No. N/A	Issuer Telephone No. (416) 843-2881
Contact Name Graham Simmonds	Contact Position CEO	Contact Telephone No. (416) 843-2881
Contact Email Address <a href="mailto:graham.simmonds@aiontherapeutic.com">graham.simmonds@aiontherapeutic.com</a>	Web Site Address <a href="http://www.aiontherapeutic.com">www.aiontherapeutic.com</a>	